Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors

Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors

Submitted by admin on July 12, 2018 - 9:17am
Source: 
CP Wire
News Tags: 
Seattle Genetics
colorectal cancer
non-small cell lung cancer
pancreatic cancer
head and neck cancer
cervical cancer
tisotumab vedotin
Genmab
clinical trials
Headline: 
Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors
snippet: 
  • Trial is Enrolling Patients with Colorectal, Non-Small Cell Lung, Pancreatic or Head and Neck Cancers
  • Earlier study demonstrated an encouraging response rate in patients with relapsed, recurrent and/or metastatic cervical cancer
  • Tisotumab vedotin is being co-developed by Seattle Genetics, Inc. and Genmab A/S.

Do Not Allow Advertisers to Use My Personal information